Aiforia is providing a uniquely comprehensive approach to breast cancer diagnostics as the majority of cases express ER and/or PR. Therefore, the two are considered to be the most significant biomarkers involved in the evaluation of breast cancer.
“Since ER and PR positivity in breast cancer are both always measured, it was only natural to develop a model for the detection of PR positive tumor cells as well. It has to be acknowledged that the biomarker, PR's, expression is dependent on the ER biomarker as well. However, it still has independent prognostic value and is associated with for example the tumor grade. Breast cancers with ER and/or PR positivity have a lower risk of recurrence of the disease so it is imperative to identify these patients reliably to be able to choose the right therapeutic option,” explains Dr. Nelli Sjöblom MD, Consulting Pathologist at Aiforia Technologies.
The field of pathology is undergoing a paradigm shift. Pathologists have relied on the same cumbersome and bias-prone technology for the past 150 years; manual slide analysis with microscopes for tasks like evaluating patient samples to aid cancer diagnostics. Aiforia is working to provide tools to overcome the challenges these traditional methods pose. Deep learning AI has the potential to bring speed and accuracy to sample evaluation and diagnostics. Therefore, enabling patients to receive faster diagnoses and to be administered personalized treatments.
The Aiforia® Clinical AI Model for Breast Cancer; PR can improve prognostic and predictive evaluation in breast cancer diagnostics through its unique functionalities. The AI model automates the detection of tumor areas as well as the calculation of PR-positive and negative cells from whole slide images (WSIs) and selected areas and even the viewing and selection of areas with high PR-positive density, or hotspots. The AI-assisted image analysis results are available with speed and consistency.
“I am proud of our team of expert pathologists, scientists, and software developers in helping us to become frontrunners in the clinical diagnostics market. This latest CE-IVD marking solidifies our rapid, continued expansion of Aiforia’s offering of AI-powered products for supporting the diagnosis of some of the world’s most prevalent cancers,” explains Jukka Tapaninen, CEO of Aiforia Technologies.
Aiforia currently offers three CE-IVD marked clinical AI models for breast cancer diagnostics as well as the CE-IVD marked PD-L1 AI model for lung cancer diagnostics. With further clinical AI models and digital tools in the pipeline to serve clinical workflows and pathologists in the diagnosis of other cancer types, Aiforia aims to be the global leader in AI-assisted tissue sample analytics.
Emma Vehviläinen, CMO, Aiforia Technologies Plc, tel. +358406675204